<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-80717" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Prasugrel </title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sampat</surname>
            <given-names>Parth J.</given-names>
          </name>
          <aff>SUNY Upstate Medical University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Wadhwa</surname>
            <given-names>Roopma</given-names>
          </name>
          <aff>South Carolina Department of Mental Health</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Parth Sampat declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Roopma Wadhwa declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>10</day>
          <month>4</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-80717.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Prasugrel is a medication used to manage and treat acute coronary syndrome undergoing percutaneous intervention. Prasugrel is a thienopyridine, an irreversible antagonist of the ADP P2Y12 receptor. The antiplatelet effect of prasugrel lasts until the lifespan of platelets. Prasugrel is a prodrug that is converted to an active and inactive metabolite by the hepatic CYP system. This activity covers the indications, dosing, contraindications, mechanism of action, and management of prasugrel in cases where it can provide therapeutic benefit.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the mechanism of action of prasugrel.</p></list-item><list-item><p>Review the indications of prasugrel.</p></list-item><list-item><p>Summarize the pharmacokinetics of prasugrel.</p></list-item><list-item><p>Explain the importance of care coordination amongst the interprofessional team to enhance patient safety for anyone using prasugrel.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=80717&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=80717">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-80717.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Platelet adhesion, activation, and aggregation play critical roles in normal hemostasis and pathological thrombosis. These factors are&#x000a0;pathologically&#x000a0;crucial in initiating intracoronary thromboses that cause acute coronary syndromes (ACS) and the ischemic complications following coronary artery interventions, including stent thrombosis and recurrent myocardial infarction.&#x000a0;The interaction of ADP with P2Y and P2Y receptors&#x000a0;enhances and sustains platelet activation; these activated platelets expose glycoprotein IIb/IIIa receptors, which crosslink with fibrin to form platelet aggregates. These aggregates&#x000a0;result in mechanical blood flow disruption and&#x000a0;can potentially embolize downstream,&#x000a0;leading to microvasculature obstruction&#x000a0;resulting in myocardial ischemia and infarction.<xref ref-type="bibr" rid="article-80717.r1">[1]</xref></p>
        <p>Prasugrel is an antiplatelet agent in the thienopyridine group.<xref ref-type="bibr" rid="article-80717.r2">[2]</xref>&#x000a0;Prasugrel is used to decrease the rate of cardiovascular events in patients with acute coronary syndrome (ACS) who are undergoing&#x000a0;percutaneous coronary intervention. Prasugrel has approval for medical management of patients with unstable angina or non-ST elevation myocardial infarction (NSTEMI) and patients with ST-elevation myocardial infarction (STEMI) managed with percutaneous coronary intervention. Prasugrel is an alternative agent to clopidogrel, with greater platelet aggregation inhibition than clopidogrel.<xref ref-type="bibr" rid="article-80717.r3">[3]</xref>&#x000a0;It has shown an increased risk of bleeding in patients receiving prasugrel compared to clopidogrel, who require urgent or emergent CABG. However, prasugrel was associated with a lower rate of mortality when compared to clopidogrel.<xref ref-type="bibr" rid="article-80717.r4">[4]</xref>&#x000a0;I was approved for use in the USA by the FDA in 2009.<xref ref-type="bibr" rid="article-80717.r5">[5]</xref></p>
      </sec>
      <sec id="article-80717.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Prasugrel is a thienopyridine, an irreversible antagonist of the ADP P2Y12 receptor.<xref ref-type="bibr" rid="article-80717.r2">[2]</xref>&#x000a0;Thienopyridine antiplatelet agents interfere with platelet activation and aggregation induced by ADP.<xref ref-type="bibr" rid="article-80717.r1">[1]</xref> The antiplatelet effect of prasugrel lasts&#x000a0;for the lifespan of platelets.</p>
        <p>
<bold>Pharmacokinetics and Pharmacodynamics</bold>
</p>
        <p>Prasugrel is a prodrug that is converted to an active thiol metabolite and inactive metabolite by the hepatic CYP system, specifically CYP2BH6, 2C9/19 (minor), and it is a CYO3A4 substrate. The active component (R- 138727) of the metabolites irreversibly binds to and blocks P2Y12&#x000a0;adenosine diphosphate (ADP) receptors, preventing GPIIb/IIIa receptor complex activation, thus reducing platelet aggregation and activation. It is rapidly absorbed and metabolized, with its active metabolite peaking approximately after 30 minutes of dosing. The mean elimination half-life of the active metabolite of prasugrel is approximately 7 hours.<xref ref-type="bibr" rid="article-80717.r6">[6]</xref>&#x000a0;The elimination of 70 percent of the drug occurs through the kidney, with roughly 25 percent in feces.<xref ref-type="bibr" rid="article-80717.r7">[7]</xref>&#x000a0;With the onset of action being 30 minutes, it attains a steady-state concentration within three days.<xref ref-type="bibr" rid="article-80717.r8">[8]</xref>&#x000a0;Platelet aggregation returns to baseline status 5&#x000a0;to 9 days following discontinuation of prasugrel, which is reflective of new platelet production.</p>
      </sec>
      <sec id="article-80717.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Prasugrel is only available in tablet formulation; therefore, its administration is only via the oral route. Administration can be without regard to the intake of a meal. When undergoing emergent primary PCI, crushing the tablets is associated with faster absorption&#x000a0;and a more rapid and higher antiplatelet effect achievable within 30 minutes of administration.<xref ref-type="bibr" rid="article-80717.r9">[9]</xref>&#x000a0;The bioavailability of prasugrel becomes reduced when it is administered via an enteral route bypassing the stomach acidity. Clinicians should consider withholding dosing at least seven days prior to any surgical procedures.</p>
        <p>
<bold>Available Dosage Forms</bold>
</p>
        <p>5 mg and 10 mg tablets</p>
        <p>
<bold>Dosing for Acute Coronary Syndromes</bold>
</p>
        <p>Loading dose: Initial loading dose of 60 mg requires prompt administration as soon as acute coronary syndrome is known.&#x000a0;</p>
        <p>Maintenance dose: The maintenance dose for people above the weight of 60 kg is 10 mg daily. There is an increased risk of bleeding in low-weight individuals (weight less than 60 kg) taking prasugrel, so a lower dose of 5 mg daily can be considered in these patients. Prasugrel 5 mg in low body weight (&#x0003c; 60 kg) individuals reduced platelet reactivity similarly to 10 mg in higher body weight individuals (&#x0003e; 60 kg).<xref ref-type="bibr" rid="article-80717.r10">[10]</xref>&#x000a0;Prasugrel administration should be in combination with aspirin.</p>
        <p>
<bold>Duration of Dual Antiplatelet Treatment After Stent Placement</bold>
</p>
        <p>As per&#x000a0;ACC/AHA dual antiplatelet therapy guidelines, at least 6&#x000a0;to 12 months of dual antiplatelet therapy (DAPT) treatment is recommended in people with ACS receiving either a bare-metal or drug-eluting stent. A shorter duration of dual antiplatelet therapy can be considered in patients with low ischemia risk and higher bleeding risk, whereas a longer duration of DAPT treatment may be reasonable&#x000a0;in patients with a higher&#x000a0;risk of ischemia and lower risk of bleeding. Decisions about the discontinuation of DAPT are individualized and based on clinical judgment.<xref ref-type="bibr" rid="article-80717.r2">[2]</xref></p>
        <p>
<bold>Use in Renal Impairment</bold>
</p>
        <p>No dosage adjustments are required; however, there is an increased risk of bleeding with moderate to severe renal impairment due to decreased drug excretion. Dosing in end-stage renal disease and patients on peritoneal or hemodialysis is undefined.</p>
        <p>
<bold>Use in Hepatic Impairment</bold>
</p>
        <p>No dosage adjustments are necessary for mild to moderate hepatic impairment (Child-Pugh class A and B). Researchers have not studied the use of prasugrel in patients with severe hepatic impairment (Child-Pugh class C); however, it generally correlates with increased bleeding.</p>
        <p>
<bold>Pregnancy and Lactation</bold>
</p>
        <p>There is no human data regarding fetal or infant risk when using prasugrel during pregnancy or breastfeeding. The maternal risk of hemorrhage exists based on the drug's mechanism of action. There is no data on whether prasugrel affects milk production.<xref ref-type="bibr" rid="article-80717.r11">[11]</xref></p>
        <p>There is no indication for dosing prasugrel in pediatric patients.</p>
      </sec>
      <sec id="article-80717.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Bleeding is the most common adverse effect associated with prasugrel, and the drug carries a black box warning for potentially fatal bleeding. Increased risk of bleeding may occur in patients with a bodyweight of less than 60 kg, recent trauma, recent surgery, and active bleeding peptic ulcer. Increased risk of bleeding is also seen in renal impairment as it is associated with decreased excretion. There is no antidote available for bleeding caused by prasugrel. If bleeding does occur, theoretically, hemostasis is achievable by a platelet transfusion. However, platelet transfusion within 4 hours of administration of prasugrel may be less effective. If possible, bleeding management should take place without stopping prasugrel, as premature discontinuation of prasugrel is associated with stent thrombosis and increased incidence of adverse cardiovascular outcomes.</p>
        <p>Thrombotic thrombocytopenic purpura (TTP) is a rare but serious adverse effect associated with thienopyridine use and usually occurs within two weeks of starting treatment.<xref ref-type="bibr" rid="article-80717.r12">[12]</xref>&#x000a0;TTP management requires urgent plasmapheresis.&#x000a0;</p>
        <p>Indigestion is the most common gastrointestinal side effect associated with prasugrel. Other adverse effects associated with prasugrel use are headache, dizziness, epistaxis, hematoma, and bruising.&#x000a0;</p>
        <p>Use of prasugrel with warfarin or NSAIDS, when used chronically, increases the risk of bleeding.</p>
      </sec>
      <sec id="article-80717.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Hypersensitivity to prasugrel or any of the components of the formulation is a contraindication for its use. Other contraindications for starting prasugrel are any pathological bleed or history of transient ischemic attack or stroke. The use of prasugrel is not recommended in patients older than 75 due to the increased risk of bleeding.</p>
        <p>Caution is advised when considering prasugrel in moderate to severe renal impairment, severe hepatic impairment, a patient history of GI bleeding or active GI ulcers/disease, and in patients with a history of recent surgery or trauma.</p>
        <p>Prasugrel use is contraindicated with the concomitant use of abrocitinib (a Janus-kinase inhibitor), because of the additive effects that can lead to life-threatening bleeding risk. There are many other drugs where caution is advised and may require therapy modification; thorough medication reconciliation is required to limit bleeding risks.<xref ref-type="bibr" rid="article-80717.r13">[13]</xref></p>
      </sec>
      <sec id="article-80717.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>While no routine laboratory tests are required, periodic checks for hemoglobin and hematocrit for signs of bleeding are prudent on a case-by-case basis.&#x000a0;</p>
      </sec>
      <sec id="article-80717.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Prasugrel causes rapid and irreversible platelet inhibition and can be associated with life-threatening bleeding in case of toxicity. Researchers observed lethality in rats with a dose of 2000 mg/kg. There is no antidote available for use in case of toxicity with prasugrel. The active metabolite of prasugrel is likely not removable via dialysis.<xref ref-type="bibr" rid="article-80717.r14">[14]</xref></p>
      </sec>
      <sec id="article-80717.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Prasugrel has extensive use among cardiologists, ED physicians, mid-level practitioners (NPs and PAs), and internists. The choice of an antiplatelet medication depends upon the clinical situation. The addition of thienopyridine to aspirin is the standard of care for patients with acute coronary syndromes and patients undergoing percutaneous coronary intervention. There have been concerns about clopidogrel treatment failure, defined as the inability to achieve adequate antiplatelet effect in an individual taking clopidogrel. An individualized DAPT approach may be potentially guided by genetic or platelet function testing; however, routine screening in percutaneous coronary intervention is not recommended. However, platelet function testing merits consideration for DAPT de-escalation.<xref ref-type="bibr" rid="article-80717.r15">[15]</xref></p>
        <p>Nurses are the ones to administer the drugs to the patients when the patients are inpatient and also the first responders when adverse effects occur during an inpatient stay. They can also provide patient counseling on dosing and signs of bleeding and serve as a contact point for ongoing care.</p>
        <p>The role of a pharmacist is essential to look for any drug-drug interaction with any medication, and they can recommend discontinuation of any drugs that can alter the effectiveness of prasugrel if they are nonessential. They are the most accessible healthcare provider for patients. They can verify dosing, counsel patients on administration and adverse events, and report any concerns to other interprofessional team members.</p>
        <p>As premature discontinuation of dual antiplatelet therapy&#x000a0;is associated with stent thrombosis, myocardial infarctions, and increased cardiovascular events, it is crucial to educate the patient regarding compliance. Regular follow-ups are essential for the monitoring of bleeding. Discontinuation of DAPT for an elective procedure is an interdisciplinary decision, and DAPT should continue for 6&#x000a0;to 12 months after PCI.</p>
        <p>Dual antiplatelet therapy requires interprofessional communication and a team approach, including primary care clinicians, specialists, nursing staff, and pharmacists, coordinating their activities and recording their findings in the patient record, so all healthcare team members operate from the same data. This approach to patient care will enhance outcomes and mitigate adverse events. [Level 5]</p>
      </sec>
      <sec id="article-80717.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=80717&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=80717">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/80717/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=80717">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-80717.s11">
        <title>References</title>
        <ref id="article-80717.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wiviott</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Antman</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Braunwald</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Prasugrel.</article-title>
            <source>Circulation</source>
            <year>2010</year>
            <month>Jul</month>
            <day>27</day>
            <volume>122</volume>
            <issue>4</issue>
            <fpage>394</fpage>
            <page-range>394-403</page-range>
            <pub-id pub-id-type="pmid">20660815</pub-id>
          </element-citation>
        </ref>
        <ref id="article-80717.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Levine</surname>
                <given-names>GN</given-names>
              </name>
              <name>
                <surname>Bates</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Bittl</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Brindis</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Fihn</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Fleisher</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Granger</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Lange</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Mack</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Mauri</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mehran</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mukherjee</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Newby</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>O'Gara</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Sabatine</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SC</given-names>
              </name>
            </person-group>
            <article-title>2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery.</article-title>
            <source>Circulation</source>
            <year>2016</year>
            <month>Sep</month>
            <day>06</day>
            <volume>134</volume>
            <issue>10</issue>
            <fpage>e123</fpage>
            <page-range>e123-55</page-range>
            <pub-id pub-id-type="pmid">27026020</pub-id>
          </element-citation>
        </ref>
        <ref id="article-80717.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Gara</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Kushner</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Ascheim</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>de Lemos</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Ettinger</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Fesmire</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Franklin</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Granger</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Krumholz</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Linderbaum</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Morrow</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Newby</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Ornato</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Ou</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Radford</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Tamis-Holland</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Tommaso</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Tracy</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Woo</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>DX</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Jacobs</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Halperin</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Albert</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Brindis</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Creager</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>DeMets</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Guyton</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Hochman</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Kovacs</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Kushner</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Ohman</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Yancy</surname>
                <given-names>CW</given-names>
              </name>
              <collab>American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines</collab>
            </person-group>
            <article-title>2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.</article-title>
            <source>Circulation</source>
            <year>2013</year>
            <month>Jan</month>
            <day>29</day>
            <volume>127</volume>
            <issue>4</issue>
            <fpage>e362</fpage>
            <page-range>e362-425</page-range>
            <pub-id pub-id-type="pmid">23247304</pub-id>
          </element-citation>
        </ref>
        <ref id="article-80717.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Goodnough</surname>
                <given-names>LT</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Poston</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Short</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Weerakkody</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Lenarz</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2012</year>
            <month>Jul</month>
            <day>31</day>
            <volume>60</volume>
            <issue>5</issue>
            <fpage>388</fpage>
            <page-range>388-96</page-range>
            <pub-id pub-id-type="pmid">22633653</pub-id>
          </element-citation>
        </ref>
        <ref id="article-80717.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baker</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Role of prasugrel, a novel P2Y(12) receptor antagonist, in the management of acute coronary syndromes.</article-title>
            <source>Am J Cardiovasc Drugs</source>
            <year>2009</year>
            <volume>9</volume>
            <issue>4</issue>
            <fpage>213</fpage>
            <page-range>213-29</page-range>
            <pub-id pub-id-type="pmid">19655817</pub-id>
          </element-citation>
        </ref>
        <ref id="article-80717.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Angiolillo</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Suryadevara</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Capranzano</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bass</surname>
                <given-names>TA</given-names>
              </name>
            </person-group>
            <article-title>Prasugrel: a novel platelet ADP P2Y12 receptor antagonist. A review on its mechanism of action and clinical development.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2008</year>
            <month>Nov</month>
            <volume>9</volume>
            <issue>16</issue>
            <fpage>2893</fpage>
            <page-range>2893-900</page-range>
            <pub-id pub-id-type="pmid">18937620</pub-id>
          </element-citation>
        </ref>
        <ref id="article-80717.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Farid</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Gillespie</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Rash</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Blair</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Kurihara</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Goldberg</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>The disposition of prasugrel, a novel thienopyridine, in humans.</article-title>
            <source>Drug Metab Dispos</source>
            <year>2007</year>
            <month>Jul</month>
            <volume>35</volume>
            <issue>7</issue>
            <fpage>1096</fpage>
            <page-range>1096-104</page-range>
            <pub-id pub-id-type="pmid">17403916</pub-id>
          </element-citation>
        </ref>
        <ref id="article-80717.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dobesh</surname>
                <given-names>PP</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor.</article-title>
            <source>Pharmacotherapy</source>
            <year>2009</year>
            <month>Sep</month>
            <volume>29</volume>
            <issue>9</issue>
            <fpage>1089</fpage>
            <page-range>1089-102</page-range>
            <pub-id pub-id-type="pmid">19698014</pub-id>
          </element-citation>
        </ref>
        <ref id="article-80717.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rollini</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Franchi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kureti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Aggarwal</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Durairaj</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Seawell</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cox-Alomar</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Zenni</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Guzman</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Suryadevara</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Antoun</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bass</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Angiolillo</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Crushed Prasugrel Tablets in Patients With&#x000a0;STEMI Undergoing Primary Percutaneous Coronary Intervention: The CRUSH Study.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2016</year>
            <month>May</month>
            <day>03</day>
            <volume>67</volume>
            <issue>17</issue>
            <fpage>1994</fpage>
            <page-range>1994-2004</page-range>
            <pub-id pub-id-type="pmid">27012781</pub-id>
          </element-citation>
        </ref>
        <ref id="article-80717.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Erlinge</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ten Berg</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Foley</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Angiolillo</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Wagner</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jakubowski</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Moser</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Small</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Bergmeijer</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>James</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Winters</surname>
                <given-names>KJ</given-names>
              </name>
            </person-group>
            <article-title>Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trial.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2012</year>
            <month>Nov</month>
            <day>13</day>
            <volume>60</volume>
            <issue>20</issue>
            <fpage>2032</fpage>
            <page-range>2032-40</page-range>
            <pub-id pub-id-type="pmid">23083774</pub-id>
          </element-citation>
        </ref>
        <ref id="article-80717.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tello-Montoliu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Seecheran</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Angiolillo</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Successful pregnancy and delivery on prasugrel treatment: considerations for the use of dual antiplatelet therapy during pregnancy in clinical practice.</article-title>
            <source>J Thromb Thrombolysis</source>
            <year>2013</year>
            <month>Oct</month>
            <volume>36</volume>
            <issue>3</issue>
            <fpage>348</fpage>
            <page-range>348-51</page-range>
            <pub-id pub-id-type="pmid">23143651</pub-id>
          </element-citation>
        </ref>
        <ref id="article-80717.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jacob</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dunn</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Qureshi</surname>
                <given-names>ZP</given-names>
              </name>
              <name>
                <surname>Bandarenko</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kwaan</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Pandey</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>McKoy</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Barnato</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Winters</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Cursio</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Weiss</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Raife</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Carey</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Sarode</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kiss</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Danielson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ortel</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>WF</given-names>
              </name>
              <name>
                <surname>Rock</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Matsumoto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fujimura</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>XL</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Armstrong</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Raisch</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Bennett</surname>
                <given-names>CL</given-names>
              </name>
            </person-group>
            <article-title>Ticlopidine-, clopidogrel-, and prasugrel-associated thrombotic thrombocytopenic purpura: a 20-year review from the Southern Network on Adverse Reactions (SONAR).</article-title>
            <source>Semin Thromb Hemost</source>
            <year>2012</year>
            <month>Nov</month>
            <volume>38</volume>
            <issue>8</issue>
            <fpage>845</fpage>
            <page-range>845-53</page-range>
            <pub-id pub-id-type="pmid">23111862</pub-id>
          </element-citation>
        </ref>
        <ref id="article-80717.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Douros</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Basedow</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cui</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Enders</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tagalakis</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Effectiveness and safety of direct oral anticoagulants with antiplatelet agents in patients with venous thromboembolism: A multi-database cohort study.</article-title>
            <source>Res Pract Thromb Haemost</source>
            <year>2022</year>
            <month>Jan</month>
            <volume>6</volume>
            <issue>1</issue>
            <fpage>e12643</fpage>
            <pub-id pub-id-type="pmid">35036824</pub-id>
          </element-citation>
        </ref>
        <ref id="article-80717.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martin</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Houssany-Pissot</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zlotnik</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Godier</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>[Management of the bleeding risk associated with antiplatelet agents].</article-title>
            <source>Rev Med Interne</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>38</volume>
            <issue>7</issue>
            <fpage>467</fpage>
            <page-range>467-473</page-range>
            <pub-id pub-id-type="pmid">28528236</pub-id>
          </element-citation>
        </ref>
        <ref id="article-80717.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sibbing</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Aradi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Alexopoulos</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ten Berg</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bhatt</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Bonello</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Collet</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Cuisset</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Franchi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Gross</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gurbel</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jeong</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Mehran</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Moliterno</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Neumann</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Pereira</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Price</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Sabatine</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>So</surname>
                <given-names>DYF</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Storey</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Tantry</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Trenk</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Valgimigli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Waksman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Angiolillo</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Updated Expert Consensus Statement on Platelet Function and Genetic Testing for&#x000a0;Guiding P2Y<sub>12</sub> Receptor Inhibitor Treatment in Percutaneous Coronary&#x000a0;Intervention.</article-title>
            <source>JACC Cardiovasc Interv</source>
            <year>2019</year>
            <month>Aug</month>
            <day>26</day>
            <volume>12</volume>
            <issue>16</issue>
            <fpage>1521</fpage>
            <page-range>1521-1537</page-range>
            <pub-id pub-id-type="pmid">31202949</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
